BG104075A - Комбинирано лечение, включващо аторвастатин и противохипертонично средство - Google Patents

Комбинирано лечение, включващо аторвастатин и противохипертонично средство

Info

Publication number
BG104075A
BG104075A BG104075A BG10407500A BG104075A BG 104075 A BG104075 A BG 104075A BG 104075 A BG104075 A BG 104075A BG 10407500 A BG10407500 A BG 10407500A BG 104075 A BG104075 A BG 104075A
Authority
BG
Bulgaria
Prior art keywords
antihypertonic
patients
combinations
atorvastatin
combined treatment
Prior art date
Application number
BG104075A
Other languages
English (en)
Other versions
BG64724B1 (bg
Inventor
Robert Scott
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG104075A publication Critical patent/BG104075A/bg
Publication of BG64724B1 publication Critical patent/BG64724B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Изобретението се отнася до фармацевтична комбинация на аторвастатин и негова фармацевтично приемлива сол и противохипертонично средство-АСЕ-инхибитор, по-специално рамиприл или негова фармацевтично приемлива сол, до китове, съдържащи тази комбинация, и до приложението им за лечение на ангина пекторис, атеросклероза, комбинация от високо кръвно налягане и хиперлипидемия и за лечение на пациенти с риск от сърдечни заболявания.
BG104075A 1997-08-29 2000-01-13 Комбинирано лечение, включващо аторвастатин и противохипертонично средство BG64724B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5727697P 1997-08-29 1997-08-29

Publications (2)

Publication Number Publication Date
BG104075A true BG104075A (bg) 2000-09-29
BG64724B1 BG64724B1 (bg) 2006-01-31

Family

ID=22009602

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104075A BG64724B1 (bg) 1997-08-29 2000-01-13 Комбинирано лечение, включващо аторвастатин и противохипертонично средство

Country Status (41)

Country Link
US (2) US20020099046A1 (bg)
EP (1) EP1009400B1 (bg)
JP (2) JP2001514223A (bg)
KR (3) KR20010022477A (bg)
CN (3) CN1473567A (bg)
AP (1) AP1191A (bg)
AR (1) AR016399A1 (bg)
AT (1) ATE285767T1 (bg)
AU (1) AU740424B2 (bg)
BG (1) BG64724B1 (bg)
BR (1) BR9811556A (bg)
CA (1) CA2296723A1 (bg)
CO (1) CO4970724A1 (bg)
DE (1) DE69828413T2 (bg)
DZ (1) DZ2595A1 (bg)
EA (1) EA200000012A1 (bg)
EG (1) EG24678A (bg)
ES (1) ES2234134T3 (bg)
GT (1) GT199800126A (bg)
HR (1) HRP980474A2 (bg)
HU (1) HUP0004318A3 (bg)
ID (1) ID24118A (bg)
IL (2) IL133962A0 (bg)
IS (1) IS5341A (bg)
MA (1) MA26536A1 (bg)
MY (1) MY121008A (bg)
NO (1) NO323987B1 (bg)
NZ (2) NZ502280A (bg)
OA (1) OA11291A (bg)
PA (1) PA8457901A1 (bg)
PE (1) PE107099A1 (bg)
PL (1) PL339091A1 (bg)
PT (1) PT1009400E (bg)
SA (1) SA98190603B1 (bg)
SK (1) SK1432000A3 (bg)
TN (1) TNSN98155A1 (bg)
TR (1) TR200000563T2 (bg)
UY (1) UY25155A1 (bg)
WO (1) WO1999011260A1 (bg)
YU (1) YU2000A (bg)
ZA (1) ZA987839B (bg)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
EP1063991A1 (en) * 1998-03-17 2001-01-03 Warner-Lambert Company Llc Statin-matrix metalloproteinase inhibitor combinations
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
AU2007200367B2 (en) * 1999-02-06 2010-04-08 Astrazeneca Ab Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
US7125897B1 (en) 1999-09-24 2006-10-24 Vasogen Ireland Limited Combined therapies for atherosclerosis treatment
FR2803525B1 (fr) * 2000-01-06 2002-05-03 Sod Conseils Rech Applic Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
JP4102664B2 (ja) 2000-07-19 2008-06-18 ノバルティス アクチエンゲゼルシャフト バルサルタン塩
WO2002017913A1 (fr) * 2000-08-30 2002-03-07 Sankyo Company, Limited Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque
US7018649B2 (en) * 2000-10-23 2006-03-28 Euro-Celtique, S.A. Felodipine transdermal device and methods
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
WO2003007993A1 (en) * 2001-07-19 2003-01-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AU2003278896B2 (en) * 2002-06-20 2009-10-01 The Governors Of The University Of Alberta Dichloroacetate in combination with cardioprotective or hemodynamic drugs
EP1539140A4 (en) * 2002-06-27 2005-12-07 Sb Pharmco Inc CARVEDILOLHYDOBROMID
BR0312102A (pt) * 2002-06-27 2007-05-29 Sb Pharmco Inc sais de fosfato de carvedilol e/ou seus solvatos, composições correspondentes, e/ou métodos de tratamento
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
EP1553941A1 (en) * 2002-10-16 2005-07-20 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US8734850B2 (en) * 2003-11-25 2014-05-27 Flamel Technologies Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
US20050169994A1 (en) * 2003-11-25 2005-08-04 Burke Matthew D. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
JP2007512372A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
KR20050092519A (ko) * 2004-03-16 2005-09-22 화이자 인코포레이티드 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
WO2005099700A1 (en) * 2004-04-06 2005-10-27 Merck & Co., Inc. Methods for the treatment of hypertension
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
AU2005280058B2 (en) * 2004-08-25 2010-09-02 Essentialis, Inc. Pharmaceutical formulations of potassium ATP channel openers and uses thereof
ES2369787T3 (es) * 2005-02-17 2011-12-07 Chiesi Farmaceutici S.P.A. Combinaciones terapéuticas de manidipina y simvastatina.
ES2558799T3 (es) * 2006-03-29 2016-02-08 Kowa Company, Ltd. Agente reductor de triglicéridos y agente de mejora del hiperinsulinismo
EP2086519B1 (en) * 2006-10-30 2017-06-21 HanAll Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors
CN102065847A (zh) 2008-04-29 2011-05-18 韩诺生物制约株式会社 含有血管紧张素-ⅱ受体阻断剂的药物制剂
CZ301299B6 (cs) * 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
NZ594738A (en) * 2009-01-23 2013-11-29 Hanmi Science Co Ltd Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
SI23149A (sl) * 2009-09-21 2011-03-31 Silverstone Pharma Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
RU2481124C1 (ru) * 2011-10-27 2013-05-10 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения
CN102671198A (zh) * 2011-12-17 2012-09-19 东莞达信生物技术有限公司 一种降压降脂复方药及其制备方法
KR20140028971A (ko) * 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
BR112015022103A2 (pt) * 2013-03-12 2017-07-18 Lg Life Sciences Ltd composição farmacêutica, método para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para prevenir ou tratar uma doença
CN104173420A (zh) * 2013-05-20 2014-12-03 广州诺氏刘生物科技有限公司 一种治疗急性肾衰竭的药物
AU2015335841B2 (en) 2014-10-23 2020-06-25 Arena Pharmaceuticals, Inc. Method of treating conditions related to the PGI2 receptor
CN112933093A (zh) * 2015-06-30 2021-06-11 韩美药品株式会社 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂
FR3040303B1 (fr) * 2015-08-27 2019-04-05 Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
CN105232555A (zh) * 2015-11-19 2016-01-13 哈尔滨圣吉药业股份有限公司 一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法
US20200315233A1 (en) * 2016-06-02 2020-10-08 Ana Pharmaceuticals, Inc. Methods and compositions for treatment of hypercalciuria and nephrolithiasis
KR20240096848A (ko) 2017-01-25 2024-06-26 더 조지 인스티튜트 포 글로벌 헬스 고혈압의 치료를 위한 조성물
KR20220119169A (ko) 2017-03-01 2022-08-26 아레나 파마슈티칼스, 인크. Pgi2-수용체 효능제를 포함하는 조성물 및 그의 제조 방법
MX2021001043A (es) * 2018-07-26 2021-04-12 The George Inst For Global Health Composiciones para el tratamiento de hipertension.
CN112826937B (zh) * 2021-03-25 2022-03-22 山东大学齐鲁医院 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
RU2158607C2 (ru) * 1995-07-03 2000-11-10 Санкио Компани Лимитед Лечение артериосклероза и ксантомы
CN1217656C (zh) * 1995-11-02 2005-09-07 沃尼尔·朗伯公司 用于调节脂浓度的方法和药物组合物

Also Published As

Publication number Publication date
GT199800126A (es) 2000-01-29
PE107099A1 (es) 1999-11-06
IS5341A (is) 2000-01-14
HRP980474A2 (en) 1999-06-30
CN1268053A (zh) 2000-09-27
CN1473567A (zh) 2004-02-11
BG64724B1 (bg) 2006-01-31
EA200000012A1 (ru) 2000-08-28
PL339091A1 (en) 2000-12-04
CN1473566A (zh) 2004-02-11
UY25155A1 (es) 2000-12-29
BR9811556A (pt) 2000-08-22
ZA987839B (en) 2000-02-28
NO323987B1 (no) 2007-07-30
TNSN98155A1 (fr) 2005-03-15
YU2000A (sh) 2002-12-10
IL133962A0 (en) 2001-04-30
DZ2595A1 (fr) 2003-02-22
CO4970724A1 (es) 2000-11-07
CA2296723A1 (en) 1999-03-11
US20020099046A1 (en) 2002-07-25
AP1191A (en) 2003-07-19
MY121008A (en) 2005-12-30
EP1009400A1 (en) 2000-06-21
ATE285767T1 (de) 2005-01-15
SK1432000A3 (en) 2000-12-11
IL133962A (en) 2006-07-05
NZ502280A (en) 2002-11-26
PT1009400E (pt) 2005-02-28
AU740424B2 (en) 2001-11-01
SA98190603B1 (ar) 2006-07-04
HUP0004318A3 (en) 2002-10-28
US20030199492A1 (en) 2003-10-23
HUP0004318A2 (hu) 2001-05-28
KR20040106591A (ko) 2004-12-17
ID24118A (id) 2000-07-06
KR20030015394A (ko) 2003-02-20
AP9801332A0 (en) 1998-09-30
AR016399A1 (es) 2001-07-04
KR20010022477A (ko) 2001-03-15
DE69828413T2 (de) 2005-12-08
DE69828413D1 (de) 2005-02-03
EG24678A (en) 2010-04-27
ES2234134T3 (es) 2005-06-16
OA11291A (en) 2003-08-25
JP2001514223A (ja) 2001-09-11
AU8458998A (en) 1999-03-22
MA26536A1 (fr) 2004-12-20
NZ530630A (en) 2005-05-27
WO1999011260A1 (en) 1999-03-11
TR200000563T2 (tr) 2000-07-21
JP2005041875A (ja) 2005-02-17
NO20000996L (no) 2000-04-27
EP1009400B1 (en) 2004-12-29
NO20000996D0 (no) 2000-02-28
PA8457901A1 (es) 2000-05-24

Similar Documents

Publication Publication Date Title
BG104075A (bg) Комбинирано лечение, включващо аторвастатин и противохипертонично средство
BG104177A (bg) Фармацевтичен състав и използването му като лекарствено средство
EA200300155A1 (ru) Терапевтическая комбинация ингибитора сетр и аторвастатина
BG104076A (bg) Комбинирано лечение включващо амплодипин и статиново съединение
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
DE50008336D1 (de) Mehrschichttablette zur verabreichung einer fixen kombination von tramadol und diclofenac
WO2002102394A3 (en) Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport
HUP0104249A2 (hu) Szív és érrendszeri betegségekkel összefüggő megbetegedési és halálozási arányok csökkentésére szolgáló gyógyszerkészítmény angiotenzin átalakító enzim inhibitor és aldoszteron antagonista együttes alkalmazásával
CA2382387A1 (en) Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
HK1087336A1 (en) Pharmaceutical composition comprising lumiracoxib
TR200101470T2 (tr) Farmasötik bileşim terkipleri.
WO2004043341A3 (en) Treatment for hemorrhagic shock
BG106128A (bg) Обща сол на aмлодипин и аторвастатин
PT998287E (pt) Utilizacao de levobupivacaina
CA2329800A1 (en) Protein formulations
BG104179A (bg) Използване на фанхинон за лечението на болестта на алцхаймер
BG106151A (bg) Фармацевтичен комплекс
CY1106129T1 (el) Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος
BR9813098A (pt) Uso de glicosaminoglicans, preparação farmacêutica, e, combinaçào
AP1708A (en) Method for preventing or delaying catheter-based revascularization.
ECSP993240A (es) Preparaciones de combinacion farmaceutica
EP1712231A3 (en) Method for improving the pharmacokinetics of tipranavir